NCT02480374View on ClinicalTrials.gov

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
BIOLOGICAL

IMNN-001

Trial Locations (4)

35233

University of Alabama Birmingham Cancer Center, Birmingham

53226

Medical College of Wisconsin/Froedtert Hospital, Milwaukee

63110

Washington Univ. in St. Louis/Barnes Jewish Hospital, St Louis

73104

Stephenson Cancer Center, Oklahoma City

Sponsors

Lead Sponsor

Imunon
All Listed Sponsors
lead

Imunon

INDUSTRY

NCT02480374 - Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | Biotech Hunter | Biotech Hunter